305 related articles for article (PubMed ID: 34869596)
1. Molecular Strategies to Target Protein Aggregation in Huntington's Disease.
Jarosińska OD; Rüdiger SGD
Front Mol Biosci; 2021; 8():769184. PubMed ID: 34869596
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-modifying enzymes in Huntington's disease.
Sap KA; Geijtenbeek KW; Schipper-Krom S; Guler AT; Reits EA
Front Mol Biosci; 2023; 10():1107323. PubMed ID: 36926679
[TBL] [Abstract][Full Text] [Related]
3. Role of TFEB in Huntington's Disease.
Ojalvo-Pacheco J; Yakhine-Diop SMS; Fuentes JM; Paredes-Barquero M; Niso-Santano M
Biology (Basel); 2024 Apr; 13(4):. PubMed ID: 38666850
[TBL] [Abstract][Full Text] [Related]
4. Targeting the proteostasis network in Huntington's disease.
Soares TR; Reis SD; Pinho BR; Duchen MR; Oliveira JMA
Ageing Res Rev; 2019 Jan; 49():92-103. PubMed ID: 30502498
[TBL] [Abstract][Full Text] [Related]
5. Siah-1-interacting protein regulates mutated huntingtin protein aggregation in Huntington's disease models.
Latoszek E; Wiweger M; Ludwiczak J; Dunin-Horkawicz S; Kuznicki J; Czeredys M
Cell Biosci; 2022 Mar; 12(1):34. PubMed ID: 35305696
[TBL] [Abstract][Full Text] [Related]
6. Proteostasis of Huntingtin in Health and Disease.
Koyuncu S; Fatima A; Gutierrez-Garcia R; Vilchez D
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28753941
[TBL] [Abstract][Full Text] [Related]
7. Herp Promotes Degradation of Mutant Huntingtin: Involvement of the Proteasome and Molecular Chaperones.
Luo H; Cao L; Liang X; Du A; Peng T; Li H
Mol Neurobiol; 2018 Oct; 55(10):7652-7668. PubMed ID: 29430620
[TBL] [Abstract][Full Text] [Related]
8. Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington's disease.
Liu Y; Hettinger CL; Zhang D; Rezvani K; Wang X; Wang H
J Neurochem; 2014 May; 129(3):539-47. PubMed ID: 24383989
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an autophagy inducer J3 to lower mutant huntingtin and alleviate Huntington's disease-related phenotype.
Long J; Luo X; Fang D; Song H; Fang W; Shan H; Liu P; Lu B; Yin XM; Hong L; Li M
Cell Biosci; 2022 Oct; 12(1):167. PubMed ID: 36209136
[TBL] [Abstract][Full Text] [Related]
10. Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.
Zhao T; Hong Y; Li S; Li XJ
J Neurosci; 2016 Aug; 36(32):8317-28. PubMed ID: 27511006
[TBL] [Abstract][Full Text] [Related]
11. NAADP-Evoked Ca
Pereira CAS; Medaglia NC; Ureshino RP; Bincoletto C; Antonioli M; Fimia GM; Piacentini M; Pereira GJDS; Erustes AG; Smaili SS
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982672
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.
Carbo M; Brandi V; Pascarella G; Staid DS; Colotti G; Polticelli F; Ilari A; Morea V
Int J Mol Med; 2019 Dec; 44(6):2223-2233. PubMed ID: 31638189
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
14. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
Lu B; Palacino J
FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
[TBL] [Abstract][Full Text] [Related]
15. The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation.
Wong YC; Holzbaur EL
J Neurosci; 2014 Jan; 34(4):1293-305. PubMed ID: 24453320
[TBL] [Abstract][Full Text] [Related]
16. Huntingtin Ubiquitination Mechanisms and Novel Possible Therapies to Decrease the Toxic Effects of Mutated Huntingtin.
Fiorillo A; Morea V; Colotti G; Ilari A
J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945781
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
[TBL] [Abstract][Full Text] [Related]
18. Gossypol, a novel modulator of VCP, induces autophagic degradation of mutant huntingtin by promoting the formation of VCP/p97-LC3-mHTT complex.
Li XJ; Zhang YY; Fu YH; Zhang H; Li HX; Li QF; Li HL; Tan RK; Jiang CX; Jiang W; Li ZX; Luo C; Lu BX; Dang YJ
Acta Pharmacol Sin; 2021 Oct; 42(10):1556-1566. PubMed ID: 33495516
[TBL] [Abstract][Full Text] [Related]
19. Drugging unconventional targets: insights from Huntington's disease.
Yu S; Liang Y; Palacino J; Difiglia M; Lu B
Trends Pharmacol Sci; 2014 Feb; 35(2):53-62. PubMed ID: 24388390
[TBL] [Abstract][Full Text] [Related]
20. Subcellular Clearance and Accumulation of Huntington Disease Protein: A Mini-Review.
Zhao T; Hong Y; Li XJ; Li SH
Front Mol Neurosci; 2016; 9():27. PubMed ID: 27147961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
